What Is Palifermin Used For? Approved Use, Per the Label

Approved use on the US label

The Kepivance prescribing information limits the indication to that setting. It states that safety and efficacy have not been established in non-hematologic malignancies, and that Kepivance was not effective in decreasing severe mucositis with allogeneic stem cell support. Other settings below are research findings rather than approved uses.

Palifermin is a prescription biologic product studied in cancer supportive care, not a general wellness compound, and its regulatory status and labelled indication differ by jurisdiction and must be read from official product labelling rather than from this page. This page is not guidance. It summarises what published studies, reviews and guidelines examined, and it states the study type and the population or model for every claim.

What Palifermin Is, According to the Literature

A 2004 drug development profile described palifermin as a recombinant human keratinocyte growth factor, also written as rHu-KGF, developed under the designations AMJ 9701 and KGF-Amgen for mucosal injury associated with cytotoxic cancer therapy (PMID 15563240). Keratinocyte growth factor signalling acts on epithelial cells rather than on the blood forming compartment, and a 2019 review of cytoprotective agents grouped palifermin with other molecules investigated for shielding normal cells from chemotherapy toxicity in human oncology settings (PMID 30914026).

One point about the shape of the evidence base matters from the outset. The verified literature summarised here is overwhelmingly human and clinical: narrative reviews, syntheses of randomised controlled trials, a guideline, a retrospective transplant analysis, a case series and a case report. Dedicated in vitro mechanistic papers and animal pharmacology studies are not part of the citation set for this page, so no laboratory or rodent findings are asserted below.

Research Area Overview

Research Area 1: Oral Mucositis From Chemotherapy and Radiotherapy

This is the dominant research area in the palifermin literature. A 2007 review of the then current literature examined the effect of palifermin on chemotherapy induced and radiation therapy induced mucositis in cancer patients, and it was framed specifically around mucosal toxicity rather than around tumour outcomes (PMID 18632516). A 2025 review of managing strategies for chemotherapy and radiotherapy induced oral mucositis placed agents such as palifermin within a broader catalogue of preventive and symptomatic approaches used in human oncology care (PMID 39799794).

Earlier syntheses covered the same ground. A 2019 review of the prevention and treatment of chemotherapy and radiotherapy induced oral mucositis described the mucosal injury pathway and the interventions studied against it in adult cancer populations (PMID 30678228). A 2015 review of mucositis management moved from pathophysiology to pragmatic therapeutics and discussed how growth factor based and non growth factor based options have been positioned in clinical practice (PMID 26384312).

What the randomised trial evidence base looks like

A 2023 review compiled evidence from randomised controlled trials on interventions for the prevention of oral mucositis in patients receiving cancer treatment, which is the study design category that carries the most weight when researchers compare preventive options (PMID 36661723). Readers comparing interventions should note that review articles summarise trials rather than generate new patient data, so the strength of any conclusion depends on the underlying trials and on the populations those trials enrolled, a limitation discussed in the broader mucositis management literature (PMID 26384312).

Research Area 2: Hematologic Malignancy and Stem Cell Transplant Settings

Much of the palifermin research sits inside hematopoietic stem cell transplant medicine, where conditioning regimens produce intense mucosal injury. A 2014 commentary on better ways to give high dose melphalan discussed how administration of that conditioning agent is handled in transplant practice and the trade off between adequate dose intensity and toxicity to normal tissue (PMID 25133893). The 2004 development profile likewise situated palifermin within myelotoxic therapy supported by stem cell rescue (PMID 15563240).

Intestinal mucositis, not only oral mucositis

A 2014 clinical report examined the impact of palifermin on intestinal mucositis in hematopoietic stem cell transplant recipients conditioned with the BEAM regimen, extending the research question beyond the mouth to the gastrointestinal tract (PMID 23955637). That work is a single transplant population study rather than a large multicentre programme, so it is best read as one data point within the transplant literature and not as a settled answer about gastrointestinal protection (PMID 23955637).

Research Area 3: Pediatric Cancer and Transplant Patients

A 2021 update to the clinical practice guideline for the prevention of oral and oropharyngeal mucositis addressed pediatric cancer patients and pediatric hematopoietic stem cell transplant patients specifically, and guideline panels of this kind grade the strength of evidence behind each intervention rather than simply listing options (PMID 34252760). Pediatric evidence is generally thinner than adult evidence for mucositis interventions, which is why a dedicated pediatric guideline exists at all (PMID 34252760). Anyone evaluating palifermin in a pediatric context should read the current guideline text directly, since recommendations are age banded and setting specific.

Research Area 4: Cytoprotection of Normal Tissue

A 2019 review of cytoprotective agents intended to avoid chemotherapy induced side effects on normal cells reviewed this class of compounds, palifermin included, and framed the central research question as whether normal epithelium can be protected without compromising the intended antitumour activity (PMID 30914026). That question of tumour safety is a recurring theme in supportive care reviews because growth factors act on epithelial tissue, and the mucositis management literature returns to it when weighing preventive options (PMID 26384312).

Adverse Events: What Studies Report

Two small reports in the verified set describe specific events observed in patients who received palifermin. A 2008 clinical and histological study of five cases reported flexural hyperpigmentation attributed to palifermin, meaning darkening of skin in flexural areas that was examined both clinically and under the microscope (PMID 18795935). A 2006 case report described osteonecrosis of the jaw in a single hematopoietic stem cell transplant patient who received palifermin, and a single case report cannot establish causation (PMID 16984751).

Broader tolerability discussion appears inside the review literature rather than in dedicated safety papers here. The 2007 review of palifermin and treatment induced mucositis considered reported effects alongside efficacy signals (PMID 18632516), and the 2019 cytoprotection review discussed the general trade offs of protecting normal cells during cytotoxic therapy (PMID 30914026). Case series and case reports sit low on the evidence hierarchy: they flag possible associations for further study and nothing more.

Where the Evidence Is Weak, Preclinical Only, or Absent

Several topics that get attached to palifermin in general discussion are not supported by the verified literature on this page.

• Cosmetic, dermatological or anti ageing use. No paper in this set studied palifermin for cosmetic skin outcomes. The only dermatological finding cited here is the opposite direction: a five case study of flexural hyperpigmentation reported as a drug associated event (PMID 18795935).
• General wound healing or recovery outside oncology. Not addressed. The reviews cited here are confined to chemotherapy and radiotherapy induced mucosal injury in cancer populations (PMID 30678228).
• Gut health in healthy people. Not addressed. The only intestinal work cited examined transplant recipients after BEAM conditioning, a population with severe treatment induced injury (PMID 23955637).
• Solid tumour radiotherapy as a distinct, settled indication. Radiotherapy induced mucositis is discussed inside general management reviews (PMID 39799794), but no dedicated solid tumour trial is included in this citation set, so no conclusion is drawn here.
• Dosing information. No dose, schedule or route is stated anywhere on this page, because dosing is a prescribing decision and the abstracts in this citation set are not the right source for it.

How to Read This Literature

1. Check the study type. A guideline (PMID 34252760) and a synthesis of randomised controlled trials (PMID 36661723) carry different weight from a single case report (PMID 16984751).
2. Check the population. Findings in transplant recipients conditioned with BEAM (PMID 23955637) do not automatically transfer to other regimens or to pediatric patients (PMID 34252760).
3. Check the date. Mucositis management has been revisited repeatedly, from 2015 (PMID 26384312) through 2025 (PMID 39799794), and positioning of individual agents can shift between reviews.

For broader background on how peptide safety questions are framed in the research literature, see Are Peptides Safe?.

Closing Note

Palifermin is a prescription biologic product studied in cancer supportive care, not a general wellness compound, and its regulatory status and labelled indication differ by jurisdiction and must be read from official product labelling rather than from this page. This page is not guidance. This page is for educational purposes only and is not medical advice; consult a licensed physician about any medical question or decision. The research described above concentrates on treatment induced oral and intestinal mucositis in cancer and transplant populations (PMID 18632516, PMID 36661723), and nothing here should be read as a statement about what any individual outcome would be.

References

• Managing strategies of chemotherapy and radiotherapy-induced oral mucositis (Cancer Treatment Reviews, 2025)
• Prevention and Treatment of Chemotherapy and Radiotherapy Induced Oral Mucositis (Medicina, 2019)
• Interventions for the Prevention of Oral Mucositis in Patients Receiving Cancer Treatment: Evidence from Randomised Controlled Trials (Current Oncology, 2023)
• Clinical practice guideline for the prevention of oral and oropharyngeal mucositis in pediatric cancer and hematopoietic stem cell transplant patients: 2021 update (European Journal of Cancer, 2021)
• Palifermin: AMJ 9701, KGF-Amgen, recombinant human keratinocyte growth factor, rHu-KGF (Drugs in R&D, 2004)
• Cytoprotective Agents to Avoid Chemotherapy Induced Side effects on Normal Cells: A Review (Current Cancer Drug Targets, 2019)
• Not too little, not too much, just right! (Better ways to give high dose melphalan) (Bone Marrow Transplantation, 2014)
• Palifermin in a hematopoietic stem cell transplant patient with osteonecrosis of the jaw (Journal of Oncology Pharmacy Practice, 2006)
• The effect of palifermin on chemotherapy and radiation therapy-induced mucositis: a review of the current literature (Supportive Cancer Therapy, 2007)
• Palifermin-induced flexural hyperpigmentation: a clinical and histological study of five cases (British Journal of Dermatology, 2008)
• Impact of palifermin on intestinal mucositis of HSCT recipients after BEAM (Bone Marrow Transplantation, 2014)
• Management of Mucositis During Chemotherapy: From Pathophysiology to Pragmatic Therapeutics (Current Oncology Reports, 2015)